Firmagon

Firmagon is the brand name for degarelix, a gonadotropin-releasing hormone (GnRH) receptor antagonist developed for the treatment of advanced hormone-dependent prostate cancer in adult men. Unlike GnRH agonists, degarelix provides rapid suppression of testosterone without an initial testosterone surge, reducing the risk of tumor flare in some patients.

Degarelix works by binding directly to GnRH receptors in the pituitary gland, suppressing the release of luteinizing hormone and follicle-stimulating hormone. The resulting drop in testosterone levels to castration range occurs within a few days and is maintained with ongoing dosing.

Administration typically involves subcutaneous injections. The initial loading dose is 240 mg, given as two 120 mg injections on day 0, followed by maintenance injections of 80 mg every 28 days. The dosing schedule may vary by country and labeling, so clinicians follow the specific product instructions.

Clinical use of Firmagon is for adults with advanced prostate cancer where testosterone suppression is desired. Its rapid onset and lack of testosterone flare can be advantageous in situations requiring swift castration levels or when antiandrogen pretreatment is not preferred.

Common adverse effects include hot flashes, sweating, injection-site reactions, weight changes, and fatigue. Some patients may experience elevations in liver enzymes; rare cases of liver injury have been reported. Hypersensitivity reactions can occur, and long-term therapy may contribute to bone density changes. Liver function and overall safety should be monitored per clinical guidelines.

Firmagon is marketed by appropriate regulatory authorities in various regions; availability and labeling may vary by country.